M&A Deal Summary

Otsuka Holdings Acquires Avanir Pharmaceuticals

On December 2, 2014, Otsuka Holdings acquired medical products company Avanir Pharmaceuticals for 3.5B USD

Acquisition Highlights
  • This is Otsuka Holdings’ 1st transaction in the Medical Products sector.
  • This is Otsuka Holdings’ largest (disclosed) transaction.
  • This is Otsuka Holdings’ 2nd transaction in the United States.
  • This is Otsuka Holdings’ 2nd transaction in California.

M&A Deal Summary
Date 2014-12-02
Target Avanir Pharmaceuticals
Sector Medical Products
Buyer(s) Otsuka Holdings
Deal Type Add-on Acquisition
Deal Value 3.5B USD
Advisor(s) Centerview Partners (Financial)
Latham & Watkins (Legal)

Target

Avanir Pharmaceuticals

Aliso Viejo, California, United States
Avanir Pharmaceuticals, Inc. is a biopharmaceutical company specializing in CNS diseases. Avanir developed and launched NUEDEXTA® (dextromethorphan hydrobromide/quinidine sulfate) 20mg/10mg capsules in the US in February 2011 as the world’s first and only approved treatment for the neurologic disease pseudobulbar affect (PBA).

Search 200,500 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Otsuka Holdings

Tokyo, Japan
Category Company
Founded 2008
Sector Healthcare Services
Employees34,388
Revenue 2.02T JPY (2023)
DESCRIPTION

Otsuka Holdings engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. Otsuka Holdings was founded in 2008 and is based in Tokyo, Japan.

DEAL STATS #
Overall 3 of 9
Sector (Medical Products) 1 of 2
Type (Add-on Acquisition) 3 of 7
State (California) 2 of 3
Country (United States) 2 of 7
Year (2014) 1 of 1
Size (of disclosed) 1 of 7
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-09-05 Astex Pharmaceuticals

Dublin, California, United States

Astex Pharmaceuticals, Inc. is a provider of drug discovery, development and commercialization, committed to the fight against cancer and other life threatening diseases.

Buy $886M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2017-03-03 Neurovance

Cambridge, Massachusetts, United States

Neurovance, Inc. is a clinical stage neuroscience-focused company. Hypothesis-driven, proprietary research at Neurovance discovered and developed centanafadine (CTN), a triple reuptake inhibitor that represents a novel approach to help adults and children with ADHD, Attention-Deficit Hyperactivity Disorder.

Buy $100M
Mergr

Product

Company

Legal